Basilea Pharmaceutica Ltd. Logo

Anti-infectives research

"Without effective antibiotics, diverse fields of medicine will be severely hampered, including surgery, the care of premature infants, cancer chemotherapy, care of the critically ill, and transplantation medicine, all of which are feasible only in the context of effective antibiotic therapy."

Infectious Diseases Society of America (IDSA), 2011

Due to the high morbidity and mortality associated with infections caused by multidrug-resistant bacteria, such as Staphylococcus aureus, Enterococcus faecalis, Acinetobacter baumannii, Pseudomonas aeruginosa and Klebsiella pneumoniae the discovery of innovative agents with potent activity against these pathogens is top priority of our anti-infectives research team.

Exploratory programs

Basilea scientists are exploiting their expertise in beta-lactam chemistry for the discovery of innovative antibiotics that resist attacks by beta-lactamases such as KPC-2 and NDM-1 and of new inhibitors of beta-lactamases restoring the activity of antibiotics against which bacteria have developed resistance.

Further exploratory research projects are focused on finding novel inhibitors for targets not yet exploited by currently marketed antibiotics and therefore not facing specific resistance mechanisms. Emphasis is put on the identification of novel inhibitors of bacterial cell-wall biosynthesis and cell division.

Basilea participates in the NewDrugs4BadBugs program supported by the Innovative Medicines Initiative (IMI), the world’s largest public-private partnership in healthcare. Basilea works alongside other pharmaceutical companies, public research organizations and scientific experts to address several aspects of antimicrobial resistance and stimulate new antibiotic research.